In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.

CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as  Beijing shipping millions of doses around the world.

A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.

SinoVac has obtained conditional approval in China for its COVID-19 vaccine CoronaVac, while new clinical data released by the company show a large difference in protection rates in two separate trials, in one case barely above the WHO threshold.